期刊
ATHEROSCLEROSIS
卷 243, 期 1, 页码 339-343出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2015.09.030
关键词
Endocan; Inflammation; Atherosclerosis; Endothelial dysfunction; Cell adhesion
资金
- MSD
- AstraZeneca
- Libytec
Endothelial dysfunction is considered as an early change in atherogenesis. Raised levels of systemic inflammatory markers are associated with cardiovascular disease (CVD). Endocan (previously known as endothelial cell specific molecule-1, ESM-1), is a potential immunoinflammatory marker that may be linked to CVD. Endocan is released by vascular endothelial cells in several organs. Endocan may play an important role in regulating cell adhesion and raised plasma levels may reflect endothelial dysfunction. Endocan levels are elevated in conditions such as chronic kidney disease, renal transplant rejection, tumor progression and hypertension. Endocan is a potential inflammatory and CVD marker. Further studies are needed to assess the relevance of endocan in clinical practice. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据